Status:
COMPLETED
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Lead Sponsor:
Biogen
Conditions:
Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients w...
Eligibility Criteria
Inclusion
- Diagnosis of relapsed, low-grade or follicular B-cell lymphoma
- CD20-positive lymphoma
- Progressive, measurable disease
- Sign informed consent
- 3 weeks beyond standard therapy
- Good performance status
- Adequate hematologic, renal, and hepatic function
Exclusion
- Chronic lymphocytic leukemia
- Lesions greater than or equal to 10 cm in diameter
- CNS lymphoma
- AIDS-related lymphoma
- Pleural effusions or ascites secondary to lymphoma
- Active, opportunistic infection
- Serious nonmalignant disease
- Prior investigational therapies, including prior anti-CD20 therapy
- Recent major surgery
Key Trial Info
Start Date :
April 1 1995
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00168740
Start Date
April 1 1995
Last Update
September 15 2005
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
2
City of Hope Natioal Medical Center
Duarte, California, United States
3
Scripps Memorial Hospital
La Jolla, California, United States
4
UCSD Stem Cell Laboratory
La Jolla, California, United States